India, Feb. 4 -- Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, reflecting improved gross margins, sharply lower R&D expenses and 7 percent sales growth. However, both adjusted earnings per share and quarterly sales missed analysts' estimates. The company also provided a weak guidance for the full-year 2025.
In pre-market activity on the NYSE, MRK shares are trading at $91.20, down $8.59 or 8.61 percent.
"We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, which continues to benefit more patients with cancer globally, the successful launch of WINREVAIR and strong performance of our Animal Health bus...